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Abstract Pharmacogenomics is emerging as a popular
type of study for human genetics in recent years. This is
primarily due to the many success stories and high poten-
tial for translation to clinical practice. In this review, the
strengths and limitations of pharmacogenomics are dis-
cussed as well as the primary epidemiologic, clinical trial,
and in vitro study designs implemented. A brief discussion
of molecular and analytic approaches will be reviewed.
Finally, several examples of bench-to-bedside clinical
implementations of pharmacogenetic traits will be descri-
bed. Pharmacogenomics continues to grow in popularity
because of the important genetic associations identified that
drive the possibility of precision medicine.
Introduction
Personalized medicine, or more recently coined precision
medicine (Khoury et al. 2012), has advanced as one of the
predominant strategic initiatives and goals of the next
decade for many pharmaceutical companies, biotech insti-
tutes, academic medical centers, and the National Institutes
of Health. The primary goal of this type of initiative is to
treat patients with the correct dose of the appropriate
medication based on their individual demographic and
genomic makeup (Khoury et al. 2012; Mirnezami et al.
2012; Garay and Gray 2012). Pharmacogenetics and
pharmacogenomics have made the dreams of precision
medicine a reality. Pharmacogenetics is the study of a single
genetic variant with a drug response phenotype, such as
treatment responders and non-responders (i.e. assessment of
drug efficacy) or a serious adverse side effect (i.e. drug
toxicity). As molecular technologies to assay the entire
genome have developed and genome-wide association
studies (GWAS) emerged, so did pharmacogenomics (sur-
veying the entire genome for associations with drug
response phenotypes). As with other genetic traits and dis-
eases, it is hypothesized that variability in drug response is
due to underlying individual variation in genetic architec-
ture. This drug response can include efficacy, serious
adverse events, toxicity, or variability in target or mainte-
nance dose. In general, pharmacogenomic studies and
analysis approaches for these types of studies are very
similar to standard genetic epidemiology studies for com-
plex diseases, however, there are some subtleties that
should be considered and these will be described in this
review.
Efforts in pharmacogenomics have been fruitful and as
such, very satisfying to researchers for many reasons.
When genetic or genomic associations are identified for a
particular drug adverse event, such that an individual with
a certain genotype has a significantly increased risk to
develop such a reaction upon drug exposure, this result can
immediately be useful to patients and physicians in a
clinic; assuming of course that an alternative treatment is
available. Similarly if the genotype of a patient can be
useful to predict the proper dose of a medication, this
association also has clinical utility whereby a physician can
use this genotype information to guide their dosing.
Associations such as these have the possibility to make an
impact on human health much more rapidly than genomic
associations with complex disease risk such as type II
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diabetes or Crohn’s disease. It is not to say that such
associations are not of critical importance to progress in the
field and future drug development, diagnostics, or pre-
vention strategies. However, translating complex disease
risk associations into clinical practice requires additional
years of research.
Another reason that pharmacogenomics has become a
significant research area in human genetics is that the effect
size for many identified genetic associations for pharmac-
ogenomic traits are much larger than those for common,
complex diseases. Table 1 shows a selected number of
genetic associations for complex diseases as well as
pharmacogenomic traits extracted from the NHGRI
GWAS catalog which captures most of the genome-wide
associations identified in GWAS (Hindorff et al. 2009)
(http://www.genome.gov/gwastudies/). If one compares the
odds ratio for the selected pharmacogenomic traits (the first
four examples in Table 1) to those of the complex disease
traits (the last three examples in Table 1), most of the
effect sizes for the drug response phenotypes are much
stronger. This allowed these pharmacogenomic associa-
tions to be identified with a smaller sample size (tens to
hundreds of individuals in pharmacogenomics, where
complex trait studies often need thousands to tens of
thousands of individuals). Of course, this also means that
the confidence intervals on the odds ratio estimates will be
larger and the estimates may be biased and imprecise
(Hosmer 2000; Harrell et al. 2001), however, many of these
associations have been replicated. So while the effect
estimates may not be precise, they are predominantly larger
than those for complex disease phenotypes (the last three
examples in Table 1). This difference in effect size may be
due to the known, large environmental factor that is the
drug exposure—which is not always present or known in
complex traits.
Finally, for some pharmacogenomics outcomes the
study is relatively straight forward to design because the
drug in question is well characterized and its mechanism of
action is well known. This makes targeted genotyping or
sequencing experiments feasible to design and implement.
On the contrary, many drugs have an unknown mechanism
of action and/or little is known about its metabolism or
transport. This type of study lends itself to a dense, gen-
ome-wide assay (such as GWAS, exome sequencing,
exome chips, or whole-genome sequencing). So prior
knowledge about the drug can play a role as a strength or
weakness for pharmacogenomic studies and it clearly plays
an important role in the type of molecular approach
selected for the study.
A limitation of pharmacogenomics research is the reality
of study design constraints (Grady and Ritchie 2011).
Because many pharmacologic agents exert great patient
cost, both in terms of dollars as well as in disease treatment
efficacy or risk of toxicity, it is not often the case that the
study can be designed in an optimal way for genetic or
genomic research. It is, for example, unethical to have a
control group with disease who are denied drug treatment
to compare to the disease group on drug. If the drug is FDA
approved with proven patient benefits, it is not advisable to
deny treatment to patients specifically to control the
genomic study design. Therefore, it is more often the case
that performing an exposed-versus-unexposed study is not
possible. However, designs which included case-only on
drug, with and without serious adverse events can be used.
This is the most common design currently used (described
more below). Another challenge related to study design is
Table 1 Comparison of common, complex disease associations with pharmacogenomics (PGx)




10q22.3 C10orf11 4.51 (2.72–7.51) 240 cases 6 9 10-8 Kiyotani et al. (2012)
Response to statin
treatment
12p12.1 SLCO1B1 4.5 (2.60–7.70) 85 cases, 90 controls 2 9 10-9 Link et al. (2008)
Response to hepatitis
C treatment
20p13 ITPA 25 (11.11–50.0) 303 cases 2 9 10-25 Tanaka et al. (2011)
Nevirapine-induced rash 6p21.32 HLA-DRB1-
DQB1
3.1 (2.30–4.20) 201 cases 5 9 10-14 Lucena et al. (2011)
Complex disease trait
Type II diabetes 10q25.2 TCF7L2 1.46 (NR) 2,413 cases, 2,392
controls
2 9 10-15 Kho et al. (2012)
Obesity 16q12.2 FTO 1.39 (1.27–1.51) 685 obese children, 685 lean
children
1 9 10-28 Meyre et al. (2009)
Age-related macular
degeneration (AMD)
1q31.3 CFH 3.11 (2.76–3.51) 2,978 cases, 2,859 controls 2 9 10-76 Chen et al. (2010)
Associations from the NHGRI GWAS Catalog (Hindorff et al. 2009)
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that most pharmacogenomic research studies are amended
to existing projects. For example, many prospective clini-
cal trials add a retrospective pharmacogenomics compo-
nent. The limitation here is that pharmacogenomics
researchers are confined to the original study design, which
may or may not fulfill their research question.
Replication of effects is another significant challenge
and limitation of pharmacogenomics studies, as compared
to complex disease association studies. To replicate
detected associations, one needs to have an independent
study with the same drug treatment and phenotype outcome
collected (adverse event, toxicity, etc.). For efficacy or
dosing outcomes, one needs not only the same drug, but
also the same dosing. For assessing drug–drug interaction
associations, one needs the same drug cocktail observed in
multiple patient cohorts. This presents a significant chal-
lenge. Often, because of this limitation, pharmacogenomics
researchers focus on functional validation of associations
in cell lines (Welsh et al. 2009; Duan et al. 2009; Huang
et al. 2007; Matsson et al. 2012; Ingle et al. 2010) or model
systems, rather than replication of effects.
Lastly, many pharmacogenomics traits or drug response
studies have very limited sample size. Drugs that exhibit
life-threatening adverse events, such as toxicity, are often
pulled from the market. Even without intervention in this
manner, many adverse events are quite rare. So while the
effect size if often larger for pharmacogenomic traits, the
available sample size may be appreciably smaller.
Regardless of the limitations described above, pharma-
cogenetic and pharmacogenomics studies have been extre-
mely successful in human genetics. The ability to translate
genetic associations from ‘‘bench to bedside’’, which is the
promise of translational research, has been demonstrated for
several pharmaceuticals and various drug-related pheno-
types (described in this review). It is clear that in this
GWAS era, with thousands of known genetic associations
for hundreds of traits, a type of study that has forged ahead,
with great success is pharmacogenomics. In this review, the
most common study designs for pharmacogenomics will be
described. Next, the molecular and analytic strategies suited
for pharmacogenomics will be briefly discussed. Finally, a
number of the translational success stories of pharmacog-
enomics traits will be reviewed. This manuscript will pro-
vide evidence for the impetus in pharmacogenomics as an
emerging area for human genetics.
Epidemiologic study designs for pharmacogenomics
Pharmacogenomic studies are often performed on data
collected for other pharmacologic research, although in
some cases, prospective clinical trials have been designed
specifically for pharmacogenomics testing. The three
primary epidemiologic study designs used include clinical
trials, retrospective case–control studies, or biobanks
linked to electronic health records (EHR) as shown in
Fig. 1. Each of these designs will be discussed briefly in
the following sections, including strengths and limitations
of each design. A summary of the strengths and limitations
is presented in Table 2.
Randomized clinical trials
A randomized clinical trial (RCT) is the gold standard of
study designs in drug treatment-related research (Stolberg
et al. 2004). An RCT is a well-designed study typically
focused on understanding the efficacy and/or toxicity of a
new therapeutic. Study participants are randomized to one
of multiple treatment arms, which controls confounding
and selection bias (Manolio et al. 2006). In addition, RCTs
are usually conducted in a double-blind manner, where
neither the study participants nor the researcher collecting
the data is knowledgeable of the treatment arm to which
the patient has been assigned (Stolberg et al. 2004). This
process protects the study from bias in two ways. First, the
study participants are less likely to have adherence issues,
differential recall of symptoms, or placebo effects. This is
due to the fact that participants are under the care of the
study physician and coordinators and are typically seen in
clinic at regular intervals, and they are all asked the same
questions about their treatment effects. Second, this pro-
tects the research from evaluating participants in a biased
manner (probing more for symptoms or minimizing
severity of symptoms). The randomization and blinding
processes attempt to control for heterogeneity and bias that
could contribute to the results of the study and are major
strengths of the RCT design.
Another significant strength of the RCT is the ability to
collect pristine phenotype information (i.e. outcomes
observed right after drug treatment and toxicities) as the
patient population is being closely monitored during
treatment initiation. In addition some RCTs have control
arms which allow for the true assessment of the predictive
ability of genetic markers to be realized, and to determine
if the effect is pharmacogenomic or just genetic in nature.
This provides more informative power than even the
observational clinical trial designs which can only be
prognostic. RCTs are otherwise epidemiologically sound
experiments that allow one to observe prospectively the
impact of therapeutics on the patient population. Finally,
within an RCT, a case-only design can be used to look for
gene–environment interactions where the ‘‘environment’’ is
the drug (Little et al. 2005).
The strengths of the RCTs are clear whereas the limi-
tations may or may not occur (depending on the trial
design). For example, if there is a complication or toxicity
Hum Genet (2012) 131:1615–1626 1617
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due to treatment during the trial, regardless of which arm
an individual was randomized to, their treatment may be
modified during the study to accommodate their
complications and/or changing symptoms. The safety and
well-being of the participants outweighs controlling the
proper study design. However, these issues can cause
Fig. 1 A visual display of the three primary epidemiologic study designs used in pharmacogenomics: randomized clinical trials, case–control,
and biobanks
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subsequent analyses of the trial data to be compromised.
An additional limitation is that while randomization of
study participants is attempted, it is not guaranteed.
Therefore, researchers may still need to adjust for covari-
ates that are not even distributed between groups. Another
potential issue is that of biased DNA sample collection
where not all participants are required to consent for DNA
contribution, in addition to the reality that many RCT are
multi-site studies and in some cases, not all sites collect
biospecimens for DNA extraction or they collect samples
in different ways (blood, saliva, etc.). As a result, sys-
tematic exclusion or bias of certain subgroups of partici-
pants may occur which could create significant issues with
subsequent genetic association analyses. Finally, as with
any large study followed for a period of time, there is
significant expense related to maintaining the cohort. Not
only is cost a potential issue, but also keeping track of
participants over long periods of time can be complicated,
if not impossible depending on the pharmacogenomic
endpoint of interest. Thus, the dataset generated in the end
of an RCT may be a substantially different sample size
from what was predicted at the outset of the trial.
Retrospective observational study
An alternative to the RCT which is more commonly used and
certainly less expensive is a case–control study, or retro-
spective observational study. Case–control design has
become the workhorse of genetic association studies in
human genetics, as it has been shown to be the most powerful
design for the detection of common variants associated with
common traits (Kraft and Cox 2008). In this design, partic-
ipants are enrolled based on their phenotype, or drug
response (efficacy, adverse event, toxicity, etc.), and infor-
mation regarding their exposures are collected retrospec-
tively. This includes any number of exposures (medical,
environmental, comorbidities, demographic, etc.) as well as
a DNA sample for genotyping. A major strength of the case–
control design, in addition to being a powerful approach, is
the ability to control the recruitment sample size for the cases
and controls. Typically, in pharmacogenomic studies, this
design is used in a collection of individuals who are all
receiving treatment for a particular disease. The ‘‘cases’’ and
‘‘controls’’ for the pharmacogenomic study are those affec-
ted and unaffected with some adverse event, toxicity, or the
responders and non-responders (efficacious versus non-
efficacious) to the treatment. Depending on the frequency of
the side effect or toxicity, the potential sample size collected
may vary quite a bit. Though less common, in some cases, a
case–control study could be constructed from a prospective
observational cohort study (also called a nested case–control
study) such as in (Link et al. 2008). In this design, phenotype
information is collected over time, and the case–control
study is designed subsequently, depending on the outcomes
observed and collected during the study. This type of study is
most common in clinic-based biobanks (described in the
following section). Case-only designs can also be extracted
from case–control studies, and are often done to look spe-
cifically for gene–drug interactions (Little et al. 2005). An
important consideration for the case-only design is the
assumption that the gene and the environmental factor (drug)
must not be correlated in the patient population. This
assumption is essential for the G 9 E interaction to be valid.
A limitation of the case–control design is the potential
bias introduced in any retrospective study in terms of dif-
ferential recall. The nature of a retrospective design relies
Table 2 Comparison of three study designs for pharmacogenomics
Randomized controlled trials Observational case–control Biobanks
Strengths
Little confounding Powerful analytic approach Phenotypes can be selected after sample
collection (from EHR)
Little selection bias Control recruitment sample size of cases and controls Many phenotypes are possible
Pristine phenotypes on short-term
outcomes and toxicity
Can be prospective or retrospective Patients are followed over time as they
continue in clinic
Limitations
Mid-trial changes due to toxicity can
cause problems for research analysis
Bias from differential recall Study design limited by what phenotypes/
traits collected in the EHR
Population stratification Population stratification Population stratification
Potential for bias in DNA collection Complications in phenotype collection (adherence,
changes, multiple treatments)
Data collected for clinic purposes—not
research
Cost: expensive in terms of time and
money to follow participants
Cost: most data collected at study initiation;
subsequent cost in making the data useful for
analysis
Cost: bioinformatics for phenotyping is
significant in terms of time and money
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on participants to report their past exposures, symptoms,
etc. (with the exception of the biobanks liked to electronic
health records where the information comes from the
medical record, not directly from the patient). This infor-
mation is easier for some individuals to recall than others;
which can introduce some degree of bias (Swan et al.
1992). For example, often ‘‘cases’’, or in pharmacoge-
nomics individuals who have toxic adverse events or
individuals who do not respond to treatment (non-effica-
cious), on average these individuals may be more likely to
recall their exposures including the drug, potential drug–
drug interactions, other environmental or diet exposures,
etc. because they think in depth about why their drug
treatment did not work for them. Whereas in ‘‘controls’’, or
individuals where the drug showed expected efficacy or no
toxic adverse event, they may not be as detailed in their
recall of other drugs, environmental, or diet exposures
because they have no need to. There are a number of
epidemiological survey techniques used to control this
issue, which can protect from these biases (Lash and Ahern
2012; Pathak et al. 2011; Stover et al. 2010; Hamilton et al.
2011; Pan et al. 2012; Hendershot et al. 2011).
Another limitation, which is also true of any retrospec-
tive clinical trial or biobank as well, is population stratifi-
cation. As with any other population-based genetic
association study, there is a risk of identifying allele fre-
quency differences that are due to underlying population
differences between cases and controls, rather than allele
frequency differences due to disease (Balding 2006). Much
work has been done in this area to identify evidence for
population stratification and approaches to deal with it
when it happens (Edwards and Gao 2012). In pharmacog-
enomics, an additional challenge exists when a particular
serious adverse event or toxicity is more prevalent in one
ancestral population. For example, Stevens Johnson syn-
drome (SJS) is associated with alleles in HLA and car-
bamazepine treatment and is more common in individuals
who are of Asian descent (Locharernkul et al. 2011). To
determine which alleles are associated with SJS, it is
important to compare individuals without SJS to those with
SJS from the same ancestry group. Otherwise any differ-
ences detected may be associated with ancestry group. This
challenge is expanded even further when the research is
considering individuals from admixed populations. If seg-
ments of the chromosomes originate from different
ancestral populations, mapping the region harboring sus-
ceptibility loci can be particularly challenging. Most
studies involving admixed populations will consider local
ancestry and/or admixture mapping.
Another limitation of a retrospective design is a set of
complications with study design that are typically out of
the researcher’s control. These include combination of
therapies, adherence to medication schedule, changes in
dose or drug based on patient response. These needs to be
dealt with after the data are collected and can lead to
studies requiring stratified analyses or even dropping some
individuals from the study. Lastly, the costs associated with
a case–control design are primarily at the time of sample
collection and enrollment, as all of the data are collected at
one time point. The result is additional cost in extracting
useful phenotype information from the data collected. The
extraction of phenotype can vary in complexity, based on
the depth of information collected. Despite the limitations,
the case–control design is a very common approach for
pharmacogenomics.
DNA biobanks
The third study design which has been emerging in phar-
macogenomics is a medical facility-based biobank linked
to electronic health records (EHR) (or a similar cohort
linked to medical records, White et al. 2011; Wilke et al.
2008; Kiyotani et al. 2008; Matimba et al. 2008). This is a
type of prospective, observational study. The availability of
electronic health records has been increasing dramatically
in recent years (Kho et al. 2011). The ability to conduct
genomic research from these records has been demon-
strated in a number of recent studies (Denny et al. 2011;
Crosslin et al. 2012; Kullo et al. 2011). The eMERGE
network (electronic MEdical Records and GEnomics)
which is funded by the National Human Genome Research
Institute (NHGRI) of the National Institutes of Health in
the United States, has driven this study design over the past
several years (McCarty et al. 2011). Many health care
providers, academic medical centers, and insurance pro-
viders have implemented DNA biobanks to link to their
EHR systems for research purposes. From these cohorts of
patient samples, pharmacogenomics studies can be devel-
oped. For example, an evaluation of warfarin dosing from
samples extracted from the Vanderbilt biobank, BioVU,
using genotypes from VKORC1, CYP2C9 and CYP4F2
has demonstrated the ability to extract pharmacogenom-
ics phenotype information using electronic algorithms
(Ramirez et al. 2012). In a study of tacrolimus response,
CYP3A5/CYP3A4 was identified previously to be associ-
ated with circulating drug levels and this effect was repli-
cated in the Vanderbilt DNA biobank (BioVU) (Birdwell
et al. 2012). Similar such studies can be designed and
implemented when large patient populations have been
collected with drug exposures and phenotype outcomes
(such as adverse events or drug toxicity). This is a major
strength of this design.
Like any cohort design, a number of genetic association
studies can be constructed after the cohort has been
established and populated. However, there are also limi-
tations with this type of sample collection. The primary
1620 Hum Genet (2012) 131:1615–1626
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limitation is that the ability to perform any particular
association study relies on the availability of samples with
the particular phenotype or drug exposure of interest. Since
there is little, if any, control exerted on the types of patients
collected, it can be very difficult to have a large enough
sample size to conduct a powerful association study.
Similarly, in a biobank linked to an EHR, medical infor-
mation is collected in the arena of patient care which may
or may not have all of the necessary information for
research purposes. Finally, phenotyping the patients to
determine efficacy or drug toxicity requires significant
medical informatics algorithm development. This can have
varying levels of complexity depending on the trait, which
then relates to the cost of phenotyping, which can be
substantial for complex drug effects (such as neuropathy or
liver toxicity). Thus, the pharmacogenomics design in a
biobank linked to an EHR may be a powerful approach (as
shown above) or it may be a challenge to accumulate
sufficient sample sizes.
In vitro study design
Many pharmacogenomics studies rely on epidemiologic
designs described in the previous section, however, for
many drugs this is not a practical approach. Variation in
drug response may be due to multiple genes, each with
small effects. In these cases, large sample sizes will be
needed to identify the effects. This is unlikely to be the
case in clinical trials, prospective cohorts, etc. Another
complication is controlling potential confounding factors
such as comorbidities, dosing, and diet. For all of these
potential issues, many groups have relied on in vitro study
designs using human cell-based models for pharmacoge-
nomics discovery, as well as validation. In these experi-
ments, cell lines are perturbed with drug treatment, in
different doses, and changes in gene expression and cell
growth can be observed (Welsh et al. 2009). The in vitro
cell-based study design also has clear strengths and limi-
tations, much like each epidemiologic study design. In
terms of strengths, the experiment can be well controlled,
large numbers can be generated in a cost-effective manner,
and the samples are unlimited in terms of resources (as
more cell lines can be made as needed) (Welsh et al. 2009).
However, these studies are limited by the following: (1)
must select cell lines from one tissue, and can only be made
from certain tissues (may or may not be the right one for
the drug in question, (2) cell lines may not express
important enzymes needed for drug metabolism and
transport, and (3) establishing cell lines may damage the
cell in unknown ways, thus altering the cell’s characteristic
and subsequently the pharmacogenomics response (Welsh
et al. 2009). Still, cell lines, such as the HapMap lym-
phoblastoid cell lines (LCLs), have been used for several
pharmacogenomics studies (Duan et al. 2009; Huang et al.
2007; Watson et al. 2011a, b; Brown et al. 2011), and have
shown enormous potential.
Molecular techniques for pharmacogenomics
Pharmacogenomics studies are inherently quite similar to
standard human genetic studies; however, the phenotype is
related to treatment response rather than simply a quanti-
tative trait or disease risk. Due to the similarity, standard
molecular technologies and analytic approaches can be
applied to these studies (Grady and Ritchie 2011). For
example, in the post-GWAS era, any number of data
generation techniques can be used, depending on the sci-
entific questions and hypothesis being tested. For example,
if it is hypothesized that rare, coding variants will be most
important for the pharmacogenomics trait of interest, ex-
ome sequencing or exome chips would be the most likely
methodology of choice. Conversely, if gene expression
variation from eQTLs (expression quantitative trait loci) or
epigenetic variation are hypothesized to be most relevant,
next generation sequencing of either RNA (RNAseq) or
methylation sites (methyl-seq) may be selected instead.
With the rapid development of novel technologies, there
are a number of assays that can be considered and these
have been reviewed elsewhere (Krueger et al. 2012; Zhou
et al. 2011; Zhang et al. 2011; Ku et al. 2011). An
important consideration is also the type of tissue being
collected and the appropriate molecular technique selected.
For example, when assaying germline DNA variation,
DNA from blood (i.e. lymphocytes) would be appropriate
and sufficient. However, if DNA variation of interest is
related to somatic changes, such as in cancer, DNA from
the tumor would be more appropriate. In addition, the
comparison would typically be tumor tissue compared to a
healthy section from the same tissue; this adds additional
effort to perform such an experiment. If gene expression or
epigenetic variation in the liver is of interest, surrogate
tissue, such as blood, may be inappropriate for this
assessment as blood cells may or may not reflect the actual
relationship between drug and the organ affected by tox-
icity (i.e. liver, if metabolized by liver; skin if skin toxicity;
etc.). A full survey of these techniques is out of the scope
of this review, thus readers should be encouraged to
explore some of these references (Manolopoulos et al.
2011; Kacevska et al. 2011; Midorikawa et al. 2012).
As mentioned earlier, an additional benefit to some
pharmacogenomics studies is the knowledge of the mech-
anism of action of the drug. This can make the initial
design of the molecular study much more targeted. For
example, several companies have designed genotyping
arrays specifically focused on drug metabolism and
Hum Genet (2012) 131:1615–1626 1621
123
transport genes, such as the Affymetrix DMET chip and the
Illumina ADME chip. Platforms like this will allow for
more targeted evaluation of genes known to be related to
the drug and/or phenotype of interest. Alternatively, a
targeted exome or genome capture experiment could be
considered if there is a list of genes hypothesized to be
relevant for the drug metabolism. This approach will most
likely only be relevant until the cost of whole-genome
sequencing drops. Once the cost of sequencing the entire
genome is low enough, this will be the method of choice as
it allows one to obtain the rare variants as well as the
common variants and everything in between. Still, even if
the genes/pathways which control drug mechanism are
known, these may or may not explain variation in response.
So while this knowledge may guide the initial molecular
assays, subsequent genomic assays may be needed. This
will result in genome-wide genotyping or whole-genome
sequencing being selected as the assay of choice.
Analytic techniques for pharmacogenomics
Standard analysis techniques are typically implemented in
pharmacogenomics studies. In general, the study design
allows for standard regression methods, Chi-square tests,
Cox-proportional hazard models for time to event analysis,
or Wilcoxon tests, etc. and there is no need for specialized
statistical methods. The only caveat to this is that the
definition of case–control groups and the interpretation of
results must be carefully considered. For example, if the
case group is defined by a serious adverse side effect to
statin treatment, and the control group is a population-
based control group that includes a set of individuals who
are not exposed to statins, associations identified may be
more likely to be associated with the reason that the
‘‘cases’’ are prescribed statins, rather than the statin side
effect. It is also possible that the association is important
for the side effect. A mechanism to control for disease
indication that led to treatment is needed for a study such
as this.
Analysis techniques for pharmacogenomics have also
been extensively reviewed (Motsinger et al. 2006a, 2007;
Motsinger and Ritchie 2006; Flynn 2011; Rodin et al.
2011; Srinivasan et al. 2009). Briefly, for single SNP or
variant analysis in pharmacogenomics association studies a
large array of statistical methods can be utilized(Cantor
et al. 2010) such as Chi-square test (Greenwood 1996;
Zheng et al. 2004), Armitage trend test (Armitage 1955;
Cree et al. 2010), Kaplan–Meier survival curves (Kaplan
and Meier 1958; Huang et al. 2009), Bayesian statistics
(Stephens and Balding 2009), or data mining methods
(Coassin et al. 2010) but is commonly performed in the
framework of regression (Woodahl et al. 2008). Most of
these are performed in standard statistical analysis software
such as STATA, SAS, R, PLINK, or others. Epistasis, or
gene–gene interactions, and gene–environment interactions
can be investigated through the use of many standard sta-
tistical methods (Motsinger et al. 2007; Cordell 2009),
complex regression methods including lasso regression
(Ayers and Cordell 2010) and logic regression (Kooperberg
et al. 2001; Kooperberg and Ruczinski 2005), as well as
data mining methods such as multifactor dimensionality
reduction (MDR) (Hahn et al. 2003; Ritchie et al. 2001),
tree-based methods such as classification and regression
trees (CART) (Breiman et al. 1984) and Random Forests/
Random Jungle (Breiman 2001; Schwarz et al. 2010),
evolutionary algorithms designed for application to genetic
data are grammatical evolution neural networks (GENN)
(Turner et al. 2010a) and genetic programming neural
networks (GPNN) (Motsinger et al. 2006b). The use of a
wide variety of methods designed for gene–gene interac-
tion analysis in pharmacogenomics studies is reviewed by
Motsinger et al. (2007). For data integration methods, there
are a number of methods emerging and more being devel-
oped all the time. For example, Huang et al. (2007) have
been exploring the three-stage triangle method, where one
investigates the association of SNPs with the trait to filter the
SNP list, next these SNPs are tested for association with
gene expression, and finally, those significant results are
tested for association with the trait. Other approaches
include using pathway analysis (Emilsson et al. 2008),
Bayesian networks (Fridley et al. 2012), canonical correla-
tion analysis (Chalise et al. 2012), and neural networks
(Turner et al. 2010b; Holzinger and Ritchie 2012). We
would direct readers to these manuscripts for a more in depth
discussion of the different analytic methods appropriate for
pharmacogenomics (Grady and Ritchie 2011; Motsinger
et al. 2007; Holzinger and Ritchie 2012; Yan 2008).
Success stories of pharmacogenomics: translational
pharmacogenetics
As shown in Table 1, pharmacogenomics studies have
observed a number of great successes in recent years. An
entire area of pharmacogenomics that was not highlighted
in the current review is cancer pharmacogenomics. The
difference in cancer is that both germline DNA variation
and somatic mutations in the tumor are part of the inves-
tigation. This changes some of the study design consider-
ations described above, thus cancer is not a major focus of
this review. However, it is important to note that many of
the successes in translation of pharmacogenomics to the
clinic are in the treatment of cancer such as EGFR tyrosine
kinase inhibitors (TKIs) in the treatment of lung cancer
(Yi et al. 2009) and HER2-directed therapies in the
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treatment of HER2-positive early-stage breast cancer (Ar-
teaga et al. 2012). The following sections will highlight
some of the pharmacogenomics results that have translated
into precision medicine. All of these particular associations
have been replicated in multiple studies and are also
evaluated by the Clinical Pharmacogenetics Implementa-
tion Consortium (CPIC) of the Pharmacogenomics
Research Network (PGRN) (Relling and Klein 2011).
CPIC was established in 2009 to address the need for
interpretation of genetic association results and guidance
for clinicians so that pharmacogenetic tests could be used
wisely in clinical care (Relling and Klein 2011). CPIC
comprises physicians and researchers who are experts in
pharmacogenetics, pharmacogenomics, and laboratory
medicine many of whom are from the Pharmacogenomics
Research Network (PGRN) and PharmGKB. CPIC has
established a framework for evaluating levels of evidence
needed to justify the implementation of a pharmacogenetic
finding into clinical care. Their systematic approach is
described in Relling and Klein (2011). In this review, we
describe several success stories in pharmacogenetics with
reported associations, CPIC evaluation, and clinical
implementation (Relling and Klein 2011).
Warfarin
Warfarin is often considered the poster-child for phar-
macogenomics research. Warfarin is a widely used anti-
coagulant that needs to be closely monitored as patients
whose warfarin levels are not maintained within its very
narrow therapeutic index are at risk for clotting or bleed-
ing. Common genetic variants in two genes, CYP2C9 and
VKORC1, have been associated with dosing variability
along with several non-genetic factors, which when com-
bined, explain up to 50 % of the variability in dose
(Johnson et al. 2011). To be more specific in European
descent individuals, CYP2C9 and VKORC1 explain up to
18 and 30 % of the variability, respectively; however, in
individuals of other ancestry groups, the variants identified
in Europeans explain much less of the variability. Routine
clinical care in warfarin dosing is empirical; a physician
prescribes a dose and monitors the patient closely to pre-
vent under or over-anticoagulation (Johnson et al. 2011).
Much research is ongoing to implement genetic testing into
routine clinical care to use genotype to guide prediction of
dose, including several genetic tests that are FDA approved
(Johnson et al. 2011).
Abacavir
Abacavir is a nucleoside reverse transcriptase inhibitor
used in combination with other anti-retroviral medications
indicated for the treatment of HIV. Abacavir is generally
well-tolerated by patients, however, in 5–8 % of individ-
uals undergoing treatment, a hypersensitivity reaction
occurs (Martin et al. 2012). Symptoms of hypersensitivity
include fever, rash, fatigue, cough, gastrointestinal symp-
toms, and dyspnea (shortness of breath). A genetic variant
in HLA-B, HLA-B*57:01, is associated with this hyper-
sensitivity reaction in about 6 % of patients (Martin et al.
2012). This association has been reviewed by Martin et al.
(2012). Not only was this association observed in retro-
spective analyses of clinical trials, there was also a pro-
spective, double-blind, randomized clinical trial of a
genetic test to reduce adverse events through screening for
HLA-B*57:01 before treatment (PREDICT-1) (Mallal
et al. 2008). Based on the results of this trial and other
supporting evidence, the FDA has implemented a black
box warning in 2008 recommending that all patients be
screened for HLA-B*57:01 before abacavir treatment.
Abacavir is one of the best examples of implementation of
pharmacogenomics into routine clinical care (Martin et al.
2012).
Thiopurines
Thiopurines are a class of drugs used for nonmalignant
immunologic conditions (specifically mercaptopurine and
azathioprine), including inflammatory bowel disease,
rheumatoid arthritis, and others, as well as lymphoid
malignancies (mercaptopurine) and myeloid leukemias
(thioguanine) (Relling et al. 2011). There is substantial
evidence showing the association between TPMT geno-
type, thiopurine methyltransferase, and phenotypic vari-
ability in treatment response (Relling et al. 2011). Dosing
recommendations have been developed and implemented,
in the absence of a randomized clinical trial; however, a
reduction in thiopurine-induced adverse events has been
reported (Relling et al. 2011).
Codeine
Codeine is an opioid analgesic used for the treatment of
mild to moderately severe pain. Codeine is metabolized to
morphine by CYP2D6, which has genetic variants that
leave some individuals poor metabolizers and others
ultrarapid metabolizers. More than 80 CYP2D6 alleles have
been identified by the Cytochrome P450 Nomenclature
Committee (http://www.cypalleles.ki.se) and clinical phe-
notypes are known for some of these, but certainly not all
of them. As shown by Crews et al. (2012), a CYP2D6 score
is calculated based on their genotypes at multiple alleles in
the gene. A number of side effects have been reported for
codeine use including gastrointestinal symptoms, drowsi-
ness, dizziness, vomiting, sweating and several others
(Crews et al. 2012). Case reports have reported severe and
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even life-threatening events in ultrarapid metabolizers
(Crews et al. 2012). Genetic testing is available for
CYP2D6 in clinical care, although not performed by all
physicians prescribing codeine. Based on the evidence,
CPIC reports that alternative treatments be explored for
patients who based on genetic testing are either poor me-
tabolizers or ultrarapid metabolizers (Crews et al. 2012).
Future directions in pharmacogenomics
Similar to all complex trait research in human genetics,
pharmacogenomics is experiencing an explosion of data.
The vast amount of data is extremely exciting for
researchers, but brings with it significant challenges. For-
tunately, as discussed previously, pharmacogenomics has a
number of success stories to motivate and inspire future
research endeavors. However, it is important to recognize
that even for the traits with identified effects there is likely
to be additional heritability that can be explained (Maher
2008). While estimating this heritability in PGx precisely is
challenging (as family studies are not always readily
available), the proposed heritability of most PGx traits
exceeds that which has been explained so far. Thus, con-
sidering alternatives to the common variant hypothesis are
warranted. Much like other traits, this additional herita-
bility will be explored in:
• Rare variants, generated by genome sequencing
experiments
• Combinations of common and rare genetic variants in
polygenic and or predictive models
• Network and pathway analyses, including common
and/or rare variants
• mRNA gene expression integrated with DNA sequence
variation
• Gene–drug–environment interactions, including addi-
tional drugs and other environmental exposures
Fortunately, the barriers to data sharing are being
reduced all the time, which makes it possible to assemble
datasets with sufficient sample size to begin to consider
effects like those listed above. The future of personalized
medicine will likely involve predictive models composed
of multiple variants and perhaps gene expression and
environmental factors as well. We will learn the true
complexity of pharmacogenomic traits.
Still, several success stories have been reported
(described above) where pharmacogenomics discoveries
have been made and many of these translated into the
clinic. This process involves a significant amount of work,
and the process has been slow for even the successful
gene–drug relationships. This is due, in part, to a lack of
specific guidelines on how to adjust medications on the
basis of genetic testing results (Relling and Klein 2011). It
is the goal of the CPIC (Relling and Klein 2011) to provide
these guidelines to clinicians and laboratories. Important
considerations that go into these guidelines include the
results of pharmacogenomics studies, US Food and Drug
Administration (FDA) label changes, and commercial
sources release information for certain drugs (Relling and
Klein 2011). It is certainly the case that personalized
medicine, or precision medicine, is emerging in clinics
around the world. However, best practices for making these
translations are still in progress.
Summary
Pharmacogenomics continues to expand in popularity as
more genetic associations are uncovered. The nature of the
effects in pharmacogenomics has been predominantly
stronger and more interpretable than common disease
associations. This is partially due to the known mechanism
of action, metabolism, and transport for many pharma-
ceuticals. Another reason, and perhaps the more important
one, is that pharmacogenomics can be translated into
patient care in a near immediate course of action. For
example, if a polymorphism is identified to be associated
with drug dosing, physicians can change clinical care using
genotype in the dosing algorithm. Likewise, if a poly-
morphism is associated with a serious adverse event, an
alternative treatment could be selected for such patients.
Finally, if it is known that treatment efficacy is optimal for
one certain genotype group, while a similar drug is most
efficacious for another genotype group, therapy can be
personalized to achieve maximal success in patient care.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Armitage P (1955) Tests for linear trends in proportions and
frequencies. Biometrics 11:375–386
Arteaga CL et al (2012) Treatment of HER2-positive breast cancer:
current status and future perspectives. Nat Rev Clin Oncol
9:16–32
Ayers KL, Cordell HJ (2010) SNP selection in genome-wide and
candidate gene studies via penalized logistic regression. Genet
Epidemiol 34:879–891
Balding DJ (2006) A tutorial on statistical methods for population
association studies. Nat Rev Genet 7:781–791
Birdwell KA et al (2012) The use of a DNA biobank linked to
electronic medical records to characterize pharmacogenomic
predictors of tacrolimus dose requirement in kidney transplant
recipients. Pharmacogenet Genomics 22:32–42
Breiman L (2001) Random forests. Mach Learn 45:5–32
1624 Hum Genet (2012) 131:1615–1626
123
Breiman L, Friedman J, Olshen RA (1984) Classification and
regression trees. Chapman & Hall, New York
Brown C, Havener TM, Everitt L, McLeod H, Motsinger-Reif AA
(2011) A comparison of association methods for cytotoxicity
mapping in pharmacogenomics. Front Genet 2:86
Cantor RM, Lange K, Sinsheimer JS (2010) Prioritizing GWAS
results: a review of statistical methods and recommendations for
their application. Am J Hum Genet 86:6–22
Chalise P, Batzler A, Abo R, Wang L, Fridley BL (2012) Simulta-
neous analysis of multiple data types in pharmacogenomic
studies using weighted sparse canonical correlation analysis.
OMICS 16:363–373
Chen W et al (2010) Genetic variants near TIMP3 and high-density
lipoprotein-associated loci influence susceptibility to age-related
macular degeneration. Proc Natl Acad Sci USA 107:7401–7406
Coassin S, Brandsta¨tter A, Kronenberg F (2010) Lost in the space of
bioinformatic tools: a constantly updated survival guide for
genetic epidemiology. The GenEpi Toolbox. Atherosclerosis
209:321–335
Cordell HJ (2009) Detecting gene–gene interactions that underlie
human diseases. Nat Rev Genet 10:392–404
Cree BAC et al (2010) A major histocompatibility Class I locus
contributes to multiple sclerosis susceptibility independently
from HLA-DRB1*15:01. PLoS One 5:e11296
Crews KR et al (2012) Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines for codeine therapy in the context
of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol
Ther 91:321–326
Crosslin DR et al (2012) Genetic variants associated with the white
blood cell count in 13,923 subjects in the eMERGE Network.
Hum Genet 131:639–652
Denny JC et al (2011) Variants near FOXE1 are associated with
hypothyroidism and other thyroid conditions: using electronic
medical records for genome- and phenome-wide studies. Am J
Hum Genet 89:529–542
Duan S et al (2009) Expression and alternative splicing of folate
pathway genes in HapMap lymphoblastoid cell lines. Pharmac-
ogenomics 10:549–563
Edwards TL, Gao X (2012) Methods for detecting and correcting for
population stratification. Curr Protoc Hum Genet, Chap 1,
Unit1.22
Emilsson V et al (2008) Genetics of gene expression and its effect on
disease. Nature 452:423–428
Flynn AA (2011) Pharmacogenetics: practices and opportunities for
study design and data analysis. Drug Discov Today 16:862–866
Fridley BL, Lund S, Jenkins GD, Wang L (2012) A Bayesian
integrative genomic model for pathway analysis of complex
traits. Genet Epidemiol 36:352–359
Garay JP, Gray JW (2012) Omics and therapy—a basis for precision
medicine. Mol Oncol 6:128–139
Grady BJ, Ritchie MD (2011) Statistical optimization of pharmac-
ogenomics association studies: key considerations from study
design to analysis. Curr Pharmacogenomics Pers Med 9:41–66
Greenwood P (1996) A guide to Chi-squared testing. Wiley, New
York
Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality
reduction software for detecting gene–gene and gene-environ-
ment interactions. Bioinformatics 19:376–382
Hamilton CM et al (2011) The PhenX Toolkit: get the most from your
measures. Am J Epidemiol 174:253–260
Harrell FE (2001) Regression modeling strategies: with applications
to linear models, logistic regression, and survival analysis.
Springer, Berlin
Hendershot T et al (2011) Using the PhenX Toolkit to Add Standard
Measures to a study. Curr Protoc Hum Genet, Chap 1, Unit1.21
Hindorff LA et al (2009) Potential etiologic and functional implica-
tions of genome-wide association loci for human diseases and
traits. Proc Natl Acad Sci USA 106:9362–9367
Holzinger ER, Ritchie MD (2012) Integrating heterogeneous high-
throughput data for meta-dimensional pharmacogenomics and
disease-related studies. Pharmacogenomics 13:213–222
Hosmer D, Lemeshow S (2000) Applied logistic regression. Wiley
Interscience, New York
Huang RS et al (2007) A genome-wide approach to identify genetic
variants that contribute to etoposide-induced cytotoxicity. Proc
Natl Acad Sci USA 104:9758–9763
Huang S-W et al (2009) Validation of VKORC1 and CYP2C9 genotypes
on interindividual warfarin maintenance dose: a prospective study
in Chinese patients. Pharmacogenet Genomics 19:226–234
Ingle JN et al (2010) Genome-wide associations and functional
genomic studies of musculoskeletal adverse events in women
receiving aromatase inhibitors. J Clin Oncol 28:4674–4682
Johnson JA et al (2011) Clinical Pharmacogenetics Implementation
Consortium Guidelines for CYP2C9 and VKORC1 genotypes
and warfarin dosing. Clin Pharmacol Ther 90:625–629
Kacevska M, Ivanov M, Ingelman-Sundberg M (2011) Perspectives
on epigenetics and its relevance to adverse drug reactions. Clin
Pharmacol Ther 89:902–907
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53:457–481
Kho AN et al (2011) Electronic medical records for genetic research:
results of the eMERGE consortium. Sci Transl Med 3:79re1
Kho AN et al (2012) Use of diverse electronic medical record systems
to identify genetic risk for type 2 diabetes within a genome-wide
association study. J Am Med Inform Assoc 19:212–218
Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS (2012) A
population approach to precision medicine. Am J Prev Med
42:639–645
Kiyotani K et al (2008) Association of genetic polymorphisms in
SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Cancer Sci 99:967–972
Kiyotani K et al (2012) A genome-wide association study identifies
locus at 10q22 associated with clinical outcomes of adjuvant
tamoxifen therapy for breast cancer patients in Japanese. Hum
Mol Genet 21:1665–1672
Kooperberg C, Ruczinski I (2005) Identifying interacting SNPs using
Monte Carlo logic regression. Genet Epidemiol 28:157–170
Kooperberg C, Ruczinski I, LeBlanc ML, Hsu L (2001) Sequence
analysis using logic regression. Genet Epidemiol 21(Suppl
1):S626–S631
Kraft P, Cox DG (2008) Study designs for genome-wide association
studies. Adv Genet 60:465–504
Krueger F, Kreck B, Franke A, Andrews SR (2012) DNA methylome
analysis using short bisulfite sequencing data. Nat Methods
9:145–151
Ku CS, Naidoo N, Wu M, Soong R (2011) Studying the epigenome
using next generation sequencing. J Med Genet 48:721–730
Kullo IJ et al (2011) Complement receptor 1 gene variants are
associated with erythrocyte sedimentation rate. Am J Hum Genet
89:131–138
Lash TL, Ahern TP (2012) Bias analysis to guide new data collection.
Int J Biostat 8(2)
Link E et al (2008) SLCO1B1 variants and statin-induced myopathy–
a genomewide study. N Engl J Med 359:789–799
Little J, Sharp L, Khoury MJ, Bradley L, Gwinn M (2005) The
epidemiologic approach to pharmacogenomics. Am J Pharmac-
ogenomics 5:1–20
Locharernkul C, Shotelersuk V, Hirankarn N (2011) Pharmacogenetic
screening of carbamazepine-induced severe cutaneous allergic
reactions. J Clin Neurosci 18:1289–1294
Hum Genet (2012) 131:1615–1626 1625
123
Lucena MI et al (2011) Susceptibility to amoxicillin-clavulanate-
induced liver injury is influenced by multiple HLA class I and II
alleles. Gastroenterology 141:338–347
Maher B (2008) Personal genomes: the case of the missing
heritability. Nature 456:18–21
Mallal S et al (2008) HLA-B*5701 screening for hypersensitivity to
abacavir. N Engl J Med 358:568–579
Manolio TA, Bailey-Wilson JE, Collins FS (2006) Genes, environment
and the value of prospective cohort studies. Nat Rev Genet
7:812–820
Manolopoulos VG, Ragia G, Tavridou A (2011) Pharmacogenomics
of oral antidiabetic medications: current data and pharmacoepi-
genomic perspective. Pharmacogenomics 12:1161–1191
Martin MA et al (2012) Clinical pharmacogenetics implementation
consortium guidelines for hla-B genotype and abacavir dosing.
Clin Pharmacol Ther 91:734–738
Matimba A et al (2008) Establishment of a biobank and pharmacogenetics
database of African populations. Eur J Hum Genet 16:780–783
Matsson P et al (2012) Discovery of regulatory elements in human
ATP-binding cassette transporters through expression quantita-
tive trait mapping. Pharmacogenomics J 12:214–226
McCarty CA et al (2011) The eMERGE Network: a consortium of
biorepositories linked to electronic medical records data for
conducting genomic studies. BMC Med Genomics 4:13
Meyre D et al (2009) Genome-wide association study for early-onset
and morbid adult obesity identifies three new risk loci in
European populations. Nat Genet 41:157–159
Midorikawa Y, Tsuji S, Takayama T, Aburatani H (2012) Genomic
approach towards personalized anticancer drug therapy. Phar-
macogenomics 13:191–199
Mirnezami R, Nicholson J, Darzi A (2012) Preparing for precision
medicine. N Engl J Med 366:489–491
Motsinger AA, Ritchie MD (2006) Multifactor dimensionality
reduction: an analysis strategy for modelling and detecting
gene–gene interactions in human genetics and pharmacogenom-
ics studies. Hum Genomics 2:318–328
Motsinger AA, Ritchie MD, Dobrin SE (2006a) Clinical applications
of whole-genome association studies: future applications at the
bedside. Expert Rev Mol Diagn 6:551–565
Motsinger AA, Lee SL, Mellick G, Ritchie MD (2006b) GPNN:
power studies and applications of a neural network method for
detecting gene–gene interactions in studies of human disease.
BMC Bioinforma 7:39
Motsinger AA, Ritchie MD, Reif DM (2007) Novel methods for
detecting epistasis in pharmacogenomics studies. Pharmacoge-
nomics 8:1229–1241
Pan et al (2012) Using PhenX measures to identify opportunities for
cross-study analysis. Hum Mutat. doi:10.1002/humu.22074
Pathak J et al (2011) Evaluating phenotypic data elements for genetics and
epidemiological research: experiences from the eMERGE and PhenX
Network Projects. AMIA Summits Transl Sci Proc 2011:41–45
Ramirez AH et al (2012) Predicting warfarin dosage in European-
Americans and African-Americans using DNA samples linked to
an electronic health record. Pharmacogenomics 13:407–418
Relling MV, Klein TE (2011) CPIC: Clinical Pharmacogenetics
Implementation Consortium of the Pharmacogenomics Research
Network. Clin Pharmacol Ther 89:464–467
Relling MV et al (2011) Clinical Pharmacogenetics Implementation
Consortium guidelines for thiopurine methyltransferase geno-
type and thiopurine dosing. Clin Pharmacol Ther 89:387–391
Ritchie MD et al (2001) Multifactor-dimensionality reduction reveals
high-order interactions among estrogen-metabolism genes in
sporadic breast cancer. Am J Hum Genet 69:138–147
Rodin AS, Gogoshin G, Boerwinkle E (2011) Systems biology data
analysis methodology in pharmacogenomics. Pharmacogenom-
ics 12:1349–1360
Schwarz DF, Ko¨nig IR, Ziegler A (2010) On safari to Random Jungle:
a fast implementation of Random Forests for high-dimensional
data. Bioinformatics 26:1752–1758
Srinivasan BS et al (2009) Methods for analysis in pharmacogenom-
ics: lessons from the Pharmacogenetics Research Network
Analysis Group. Pharmacogenomics 10:243–251
Stephens M, Balding DJ (2009) Bayesian statistical methods for
genetic association studies. Nat Rev Genet 10:681–690
Stolberg HO, Norman G, Trop I (2004) Randomized controlled trials.
AJR Am J Roentgenol 183:1539–1544
Stover PJ, Harlan WR, Hammond JA, Hendershot T, Hamilton CM
(2010) PhenX: a toolkit for interdisciplinary genetics research.
Curr Opin Lipidol 21:136–140
Swan SH, Shaw GM, Schulman J (1992) Reporting and selection bias
in case-control studies of congenital malformations. Epidemiol-
ogy 3:356–363
Tanaka Y et al (2011) Genome-wide association study identified
ITPA/DDRGK1 variants reflecting thrombocytopenia in pegy-
lated interferon and ribavirin therapy for chronic hepatitis C.
Hum Mol Genet 20:3507–3516
Turner S, Dudek S, Ritchie M (2010a) Grammatical evolution of
neural networks for discovering epistasis among quantitative
trait loci. Lect Notes Comput Sci 6023:86–97
Turner SD, Dudek SM, Ritchie MD (2010b) ATHENA: a knowledge-
based hybrid backpropagation-grammatical evolution neural
network algorithm for discovering epistasis among quantitative
trait Loci. BioData Min 3:5
Watson VG, Hardison NE, Harris T, Motsinger-Reif A, McLeod HL
(2011a) Genomic profiling in CEPH cell lines distinguishes
between the camptothecins and indenoisoquinolines. Mol Cancer
Ther 10:1839–1845
Watson VG et al (2011b) Identification and replication of loci
involved in camptothecin-induced cytotoxicity using CEPH
pedigrees. PLoS One 6:e17561
Welsh M et al (2009) Pharmacogenomic discovery using cell-based
models. Pharmacol Rev 61:413–429
White CC et al (2011) CYP4A11 variant is associated with high-
density lipoprotein cholesterol in women. Pharmacogenomics J.
doi:10.1038/tpj.2011.40
Wilke RA et al (2008) Characterization of low-density lipoprotein
cholesterol-lowering efficacy for atorvastatin in a population-
based DNA biorepository. Basic Clin Pharmacol Toxicol
103:354–359
Woodahl EL et al (2008) Pharmacogenomic associations in ABCB1
and CYP3A5 with acute kidney injury and chronic kidney
disease after myeloablative hematopoietic cell transplantation.
Pharmacogenomics J 8:248–255
Yan Q (2008) The integration of personalized and systems medicine:
bioinformatics support for pharmacogenomics and drug discov-
ery. Methods Mol Biol 448:1–19
Yi HG et al (2009) Epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) are effective for leptomeningeal metas-
tasis from non-small cell lung cancer patients with sensitive
EGFR mutation or other predictive factors of good response for
EGFR TKI. Lung Cancer 65:80–84
Zhang J, Chiodini R, Badr A, Zhang G (2011) The impact of next-
generation sequencing on genomics. J Genet Genomics 38:95–109
Zheng HX et al (2004) The impact of pharmacogenomic factors on
steroid dependency in pediatric heart transplant patients using
logistic regression analysis. Pediatr Transplant 8:551–557
Zhou L, Li X, Liu Q, Zhao F, Wu J (2011) Small RNA transcriptome
investigation based on next-generation sequencing technology.
J Genet Genomics 38:505–513
1626 Hum Genet (2012) 131:1615–1626
123
